Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03596632 · ClinicalTrials.gov registry record · Phase 1
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03596632 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 8 participants.
The verdict
NCT03596632, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
Interventions
- DRUG Fenebrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-27 |
| Est. Completion | 2018-08-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03596632
The ClinicalTrials.gov registry entry for NCT03596632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fenebrutinib is the first listed.
NCT03596632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03596632 about?
NCT03596632 is a clinical study titled "Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers". The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.
What is the current status of trial NCT03596632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-07-27. Estimated completion is 2018-08-23.
What interventions are being tested in trial NCT03596632?
The interventions under investigation include: Fenebrutinib (DRUG).
Who is sponsoring clinical trial NCT03596632?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.